. 2023 Oct 13;13(1):157. doi: 10.1038/s41408-023-00930-7

Table 4.

Summary of variables, distributions of patients according to three risk group models, and 3/5-year overall survival in original models and models from the current diffuse large B-cell lymphoma cohort.

Model (N of patients)	Original study					Current study N = 5126
	Model variables (points)	Risk groups (points)	% of patients	OS-years	OS (%)	N of patients (%)	3-year OS (%)	5-year OS (%)
R-IPI [7] N = 365	Age >60 years (1) ECOG PS > 1 (1) Stage III/IV (1) EN sites >1 (1) LDH > ULN (1)	Very good (0) Good (1–2) poor (3–5)	10.0 45.0 45.0	4-	94.0 79.0 55.0	330 (6.4) 2279 (44.5) 2517 (49.1)	99.7 84.5 60.8	97.5 77.9 53.9
Matsumoto Model [33] N = 187	Stage ≥III (1) Anemia ≥Gr 2^a (1)	score 0 score 1 score 2	42.2 43.3 14.5	3-	94.6 82.0 61.4	1569 (30.6) 3015 (58.8) 543 (10.6)	86.7 70.7 54.0	80.4 64.2 48.0
ALC/R-IPI [28] N = 88	R-IPI poor (1) ALC < 0.84 × 10⁹/L (1)	L (0) I (1) H (2)	44.3 35.2 20.4	22 months	92.0 81.0 56.0	2227 (43.4) 2091 (40.8) 808 (15.8)	87.8 66.3 54.9	82.1 58.4 50.4
Models based on laboratory variables only
PA Score [32] N = 391	Albumin <35 g/L (1) PLT < 100×10⁹/L (1)	Score 0 Score 1 Score 2	62.1 32.0 5.9	5-	81.5 48.6 20.2	3509 (68.5) 1505 (29.4) 112 (2.2)	81.4 58.2 46.8	75.1 51.6 38.9
HP Index [34] N = 89	PLT < 135 × 10⁹/L (1) Hgb <120 g/L (1)	Score 0 Score 1 Score 2	47.2 43.8 9.0	3-	79.0 52.0 30.0	3106 (60.6) 1813 (35.4) 207 (4.0)	83.6 66.3 51.0	75.6 56.4 42.3

Model (N of patients)

Original study

Current study
N = 5126

Model variables (points)

Risk groups (points)

% of patients

OS-years

OS (%)

N of patients (%)

3-year OS (%)

5-year OS (%)

R-IPI [7]

N = 365

Age >60 years (1)

ECOG PS > 1 (1)

Stage III/IV (1)

EN sites >1 (1)

LDH > ULN (1)

Very good (0)

Good (1–2)

poor (3–5)

10.0

45.0

94.0

79.0

55.0

330 (6.4)

2279 (44.5)

2517 (49.1)

99.7

84.5

60.8

97.5

77.9

53.9

Matsumoto Model [33]

N = 187

Stage ≥III (1)

Anemia ≥Gr 2^a (1)

score 0

score 1

score 2

42.2

43.3

14.5

94.6

82.0

61.4

1569 (30.6)

3015 (58.8)

543 (10.6)

86.7

70.7

54.0

80.4

64.2

48.0

ALC/R-IPI [28]

N = 88

R-IPI poor (1)

ALC < 0.84 × 10⁹/L (1)

L (0)

I (1)

H (2)

44.3

35.2

20.4

22 months

92.0

81.0

56.0

2227 (43.4)

2091 (40.8)

808 (15.8)

87.8

66.3

54.9

82.1

58.4

50.4

Models based on laboratory variables only

PA Score [32]

N = 391

Albumin <35 g/L (1)

PLT < 100×10⁹/L (1)

Score 0

Score 1

Score 2

62.1

32.0

5.9

81.5

48.6

20.2

3509 (68.5)

1505 (29.4)

112 (2.2)

81.4

58.2

46.8

75.1

51.6

38.9

HP Index [34]

N = 89

PLT < 135 × 10⁹/L (1)

Hgb <120 g/L (1)

Score 0

Score 1

Score 2

47.2

43.8

9.0

79.0

52.0

30.0

3106 (60.6)

1813 (35.4)

207 (4.0)

83.6

66.3

51.0

75.6

56.4

42.3

ALC absolute lymphocyte count, ECOG PS Eastern Oncology Cooperative Group performance status, EN extranodal, Hgb hemoglobin, HP hemoglobin-platelet, LDH lactate dehydrogenase, N number, OS overall survival, PA platelet-albumin, PLT platelets, R-IPI Revised International Prognostic Index, ULN upper limit of normal.

^aAnemia grade 2: Hemoglobin <10–8.0 g/dL (Common Terminology Criteria for Adverse Events—CTCAE).